Trial · NCT04995419
Adverse events122
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 122
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Enfortumab Vedotin 1.25 mg/kg | 28 | 40 | 81 |
| other | Leukopenia | Blood and lymphatic system disorders | Enfortumab Vedotin 1.25 mg/kg | 2 | 40 | 2 |
| other | Sinus tachycardia | Cardiac disorders | Enfortumab Vedotin 1.25 mg/kg | 4 | 40 | 6 |
| other | Dry eye | Eye disorders | Enfortumab Vedotin 1.25 mg/kg | 3 | 40 | 3 |
| other | Eye discharge | Eye disorders | Enfortumab Vedotin 1.25 mg/kg | 5 | 40 | 5 |
| other | Vision blurred | Eye disorders | Enfortumab Vedotin 1.25 mg/kg | 2 | 40 | 2 |
| other | Abdominal discomfort | Gastrointestinal disorders | Enfortumab Vedotin 1.25 mg/kg | 4 | 40 | 4 |
| other | Abdominal pain | Gastrointestinal disorders | Enfortumab Vedotin 1.25 mg/kg | 4 | 40 | 5 |
| other | Abdominal pain upper | Gastrointestinal disorders | Enfortumab Vedotin 1.25 mg/kg | 5 | 40 | 5 |
| other | Constipation | Gastrointestinal disorders | Enfortumab Vedotin 1.25 mg/kg | 19 | 40 | 25 |
| other | Diarrhoea | Gastrointestinal disorders | Enfortumab Vedotin 1.25 mg/kg | 19 | 40 | 31 |
| other | Dyspepsia | Gastrointestinal disorders | Enfortumab Vedotin 1.25 mg/kg | 7 | 40 | 10 |
| other | Dysphagia | Gastrointestinal disorders | Enfortumab Vedotin 1.25 mg/kg | 6 | 40 | 10 |
| other | Flatulence | Gastrointestinal disorders | Enfortumab Vedotin 1.25 mg/kg | 2 | 40 | 2 |
| other | Gastrooesophageal reflux disease | Gastrointestinal disorders | Enfortumab Vedotin 1.25 mg/kg | 4 | 40 | 5 |
| other | Intestinal obstruction | Gastrointestinal disorders | Enfortumab Vedotin 1.25 mg/kg | 2 | 40 | 2 |
| other | Mouth ulceration | Gastrointestinal disorders | Enfortumab Vedotin 1.25 mg/kg | 7 | 40 | 7 |
| other | Nausea | Gastrointestinal disorders | Enfortumab Vedotin 1.25 mg/kg | 20 | 40 | 39 |
| other | Stomatitis | Gastrointestinal disorders | Enfortumab Vedotin 1.25 mg/kg | 2 | 40 | 2 |
| other | Vomiting | Gastrointestinal disorders | Enfortumab Vedotin 1.25 mg/kg | 12 | 40 | 17 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04995419/events